The latest from CDMOs, CMOs, and suppliers featuring CordenPharma, Lonza, National Resilience and AGC Biologics.  

Chemicals/Chemical API Manufacturing 
* CordenPharma Expands Peptide Mfg Facility 
Biologics Manufacturing 
* Lonza, Vertex Break Ground on Cell-Therapy Mfg Facility 
* AGC Biologics Expands Cell-Therapy Campus 
Formulation Development/Drug Product Manufacturing 
* National Resilience, Lifera In Joint Venture for Drug Product Facility in Saudi Arabia 

---

Chemicals/Chemical API Manufacturing 

CordenPharma Expands Peptide Mfg Facility 
CordenPharma has increased the commercial peptide production capacity at its solid-phase peptide synthesis manufacturing facility in Colorado. 

The expansion includes: (1) upgrades to their existing 10’000 L reactor volume with a batch size exceeding 400 kg (> 35 Amino Acids), and a yearly capacity of > 2 metric tons of peptide; (2) a 50% increase in downstream HPLC purification capacity; and (3) automation upgrades that allow a reduction in overall cycle time and greater scale-up consistency. 

Source: CordenPharma 

---

Biologics Manufacturing 

Lonza, Vertex Break Ground on Cell-Therapy Mfg Facility 
Lonza and Vertex Pharmaceuticals, a Cambridge, Massachusetts-based bio/pharmaceutical company, have broken ground on a cell-therapy manufacturing facility in Portsmouth, New Hampshire.  

The new facility is being built adjacent to Lonza’s existing campus in Portsmouth and is a co-investment project between the two companies. Operated by Lonza, the facility will span more than 130,000 square feet and is anticipated to generate up to 300 new jobs at peak capacity. 

Source: Lonza 

---

AGC Biologics Adds Cell-Therapy Suites to Colorado Campus 
AGC Biologics, a contract biologics manufacturer, has added three new grade B cell-therapy suites to its Longmont, Colorado facility. 

The addition provides two new process suites and one new flex suite. With more than 30,000 square feet of added space, the new suites feature modular clean room design, flexible capacity configuration, and cell therapy equipment for open and closed processes, offering autologous and allogeneic cell therapy manufacturing. 

Source: AGC Biologics 

---

Formulation Development/Drug Product Manufacturing 

National Resilience, Lifera In Joint Venture for Drug Product Facility in Saudi Arabia 
National Resilience, a CDMO of biologics and advanced therapies, and Lifera, a bio/pharmaceutical company wholly owned by the Public Investment Fund (PIF), the sovereign wealth fund of Saudi Arabia, have entered a non-binding term sheet for the development of a drug product manufacturing capacity in Riyadh, Saudi Arabia. 

Under the agreement, Resilience would provide expertise for the design, construction and commission of a cGMP drug product manufacturing facility. The joint venture will be focused on sterile injectables and other parenteral products. The proposed facility will support the aseptic filling of inactivated/bacterial vaccines, mRNA vaccines and therapeutics such as monoclonal antibodies, plasma derived products and large molecules. 

This new facility, which Lifera would be controlling owner of with Resilience owning a minority stake, aims to produce more than 125 million units annually. 

Source: National Resilience